مقالات پذیرفته شده در نهمین کنگره بین المللی زیست پزشکی
Microfluidic Platforms for Nanomedicine and Tumor Modeling in Pancreatic Cancer
Microfluidic Platforms for Nanomedicine and Tumor Modeling in Pancreatic Cancer
Elena Ebrahimian,1,*Artemis Azad Ara,2Masoud Homayouni Tabrizi ,3
1. Department of Biology, Faculty of Basic Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran 2. Department of Biology, Faculty of Basic Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran 3. Department of Biology, Ma.C., Islamic Azad University, Mashhad, Iran
Introduction: Microfluidic Platforms for Nanomedicine and Tumor Modeling in Pancreatic Cancer
With a five-year survival rate of less than 5% and an aggressive nature, pancreatic cancer continues to rank among the most deadly cancers, highlighting the critical need for novel therapeutic approaches. Because of their capacity to increase therapeutic efficacy, decrease systemic toxicity, and improve targeting, nanodrugs have become a viable strategy for overcoming the difficulties associated with PDAC therapy. For the regulated and repeatable manufacture of these nanocarriers, microfluidic devices are essential.
Methods: In this review, we conducted an extensive literature search using the PubMed, Web of Science, Scopus, and Google Scholar databases.
Results: One study examined liposomes made with microfluidic formulations that contained the hypoxia-activated prodrug Vinblastine-N-oxide (CPD100Li). Stability, selective activation in hypoxic environments, improved penetration and disruption in three-dimensional spheroids, and more robust cell inhibition in patient-derived organoids with elevated HIF1A expression were all displayed by CPD100Li. When compared to controls, CPD100Li significantly decreased tumor burden and increased survival in an orthotopic mouse model, especially when combined with gemcitabine. Another study created homogenous three-dimensional spheroids for drug sensitivity testing (gemcitabine and S-1) by encapsulating primary PDAC cells in CMC/alginate hydrogel microcapsules using microfluidic electrospray. In several instances, the clinical patient responses and the measured sensitivities were connected.
Conclusion: Although more research on pharmacokinetics, toxicity, manufacturing scalability, and clinical validation is still necessary, these results imply that combining hypoxia-activated nanocarriers with microhydrogel-based patient-derived modeling platforms has significant promise as a preclinical approach to address the hypoxic biology and resistant stroma of PDAC.